Teva- Pharmaceutical Industries Ltd

NYSE: TEVA
$17.17
-$0.20 (-1.2%)
Real Time Data Delayed 15 Min.

TEVA Stock Chart and Intraday Price

TEVA Stock Data

Asset Type Stock
Exchange NYSE
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 5 BAZEL ST, P O B 3190, PETACH TIKVA, IL
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 15,133.36M USD
Shares Outstanding 1,120,990,000
Teva Pharmaceutical Industries Ltd is a global leader in the pharmaceutical industry, specializing in the development, manufacture, and distribution of generic and specialty medicines, as well as biopharmaceutical products. With a strong presence in North America, Europe, Israel, and beyond, Teva offers a wide range of medications, including treatments for central nervous system disorders, respiratory conditions, and cancer. The company is also known for its contributions to neurodegenerative and movement disorder treatments, with notable products like COPAXONE for multiple sclerosis and AJOVY for migraine prevention. Founded in 1901 and headquartered in Tel Aviv, Israel, Teva is committed to improving health and making quality healthcare accessible worldwide.

TEVA Articles

Monday's top analyst upgrades and downgrades included Arm, General Electric, Micron Technology and Salesforce.
Friday's top analyst upgrades and downgrades included American Express, Aptiv, BorgWarner, First Horizon, Keurig Dr Pepper, Meta Platforms, MGIC Investment, Simon Property Group and Teva...
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
Friday's top analyst upgrades and downgrades included Alcoa, Charles Schwab, Cognizant Technology Solutions, IBM, Newmont, Okta, Philip Morris International, Roblox, Shopify, Teva Pharmaceutical...
Monday’s additional top analyst upgrades and downgrades were on ASML, Bank of America, Dominion Energy, Hasbro, Nio, Occidental Petroleum, Teva Pharmaceutical Industries and more.
Friday's top analyst upgrades and downgrades included AT&T, Exxon Mobil, Hasbro, Juniper Networks, Moderna, Palo Alto Networks, Snap, Teva Pharmaceutical, Under Armour and Zscaler.
Friday's additional top analyst upgrades and downgrades included Acadia Pharmaceuticals, BioCryst Pharmaceuticals, Duke Energy, Kellogg, Paramount Global, Rhythm Pharmaceuticals and Teva...
Wednesday’s top analyst upgrades and downgrades included Bluebird Bio, Caterpillar, Chesapeake Energy, Comstock Resources, Ford, Mosaic, On Semiconductor, Phillips 66, Plug Power, Ross Stores, Teva...
Tuesday's additional top analyst upgrades and downgrades were on Adobe, AstraZeneca, Best Buy, Chemours, Oracle, Royalty Pharma, Teva Pharmaceutical and Tractor Supply.
Tuesday's top analyst upgrades and downgrades included Home Depot, Intuitive Surgical, Mastercard, McDonald's, Monster Beverage, Penn National Gaming, Shoals Technologies, Starbucks, Take-Two...
Wednesday’s additional top analyst upgrades and downgrades were on Akamai, Block, Livent, Starbucks and more.
Friday’s additional top analyst upgrades and downgrades included Carnival, Farfetch, Fortinet, Materialise, Switch Teva Pharma and more.
Thursday's top analyst upgrades and downgrades included Avis Budget, Dynatrace, Norfolk Southern, PACCAR, Salesforce.com, Sherwin-Williams, Teradyne and Teva Pharmaceutical.
Six of the stocks in Berkshire Hathaway's portfolio posted losses in the second quarter. Here is how they fared.